Factor Therapeutics (ASX:FTT), a Brisbane-based company focused on developing and commercialising advanced wound care therapies, has announced the appointment of Dr David Brookes as a non-executive director.
Dr Brookes has extensive experience in the health and biotechnology industries and is currently a non-executive director of Anatara (ASX:ANR).
He has previously been a director of several other ASX-listed biotechnology companies, most recently as the chairman of genomics solutions company, RHS, which was acquired by US-based PerkinElmer in June 2018.
Dr Brookes is also urrently non-executive chairman of a private health services company, the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant. He is a fellow of the Australian College of Rural and Remote Medicine and a fellow of the Australian Institute of Company Directors.
“We are extremely pleased that such a well-respected and highly experienced medical professional as Dr Brookes is willing to join our Board at this time when we are focused on expanding our asset base with a new opportunity in the biotechnology area. His extensive experience in biotechnology will be of great value to the company now and in the future” said Factor Therapeutics chair Dr Cherrell Hirst.